



AIffinity
MOLECULAR DESIGN

Enhancing Drug Discovery with Nuclear Magnetic Resonance & Artificial Intelligence

www.aiffinity.com

info@aiffinity.com

Purkyňova 127, 612 00 Brno-Medlánky, Czech Republic


Nuclear Magnetic Resonance (NMR)

Applications:

1. Protein Structure Determination
2. Conformational Dynamics Studies
3. Molecular Interaction Studies
4. Drug screening

Challenges:


1. Technical Complexity
2. Instrumentation Cost
3. Resource Intensity
4. Protein Size Limitations




With **AI** and **Cheminformatics** we can navigate these challenges

NMR in Drug Design

- Hit Identification and Hit-to-Lead.
- Interactions with ligands, peptides and other protein.
- Purity, solubility, and structural integrity of compounds.
- Development of targeted protein degraders, cyclic dinucleotides, macrocyclic peptides, and antibody-drug conjugates.




Our solution: NMR-AI Integrated platform for Streamlined Target-to-Lead Process



1D NMR methods in Drug Design

- Photo-CIDNP, STD, WaterLOGSY
- Photo-CIDNP: more sensitive, faster (1,500 samples/day), benchtop NMR
- Protein 3D structure not necessary
- Give the atoms of the small molecule that interact with the protein (**ligand epitope**)
- We develop both **Generative AI** and **Virtual Screening solutions** incorporating ligand epitope information

NEXMR



Protein NMR

Spectral

Resolution: 2D < 3D < 4D < 5D
Sensitivity: 2D > 3D > 4D > 5D
Total time: 2D < 3D < 4D < 5D
Complexity: 2D < 3D < 4D < 5D



COMPETITORS



AIffinity
MOLECULAR DESIGN

Our competitive advantages:

- Large proteins (>20 kDa)
- IDPs

NMR



intrinsically disordered protein (IDP)

NMR



intrinsically disordered regions (IDRs)


X-ray
Cryo-EM
NMR
AlphaFold



structured protein



2D NMR spectrum




AIffinity
MOLECULAR DESIGN

www.aiffinity.com


info@aiffinity.com

Purkyřova 127, 612 00 Brno-Medlány, Czech Republic

The Fundamental Problem of Protein NMR



Streamlining NMR: Reducing Human Input with 4D-GRAPHS




4D-CHAINS (precursor of 4D-GRAPHS) case studies


Nature Commun.

all-atom resonance assignment and structure determination from 3x 4D spectra [Evangelidis et al., 2018]

133 aa




145 aa



198 aa




248 aa




Nature Structural & Molecular Biology

Double-stranded β -helix




synthetic protein

Nature Commun.



protein-peptide

Nature Commun.




protein-protein

4D-GRAPHS: protein structure from fewer spectra



Chemical shift
assignment
(4D-GRAPHS)

4D HCNH NOESY
4D HCCH NOESY
4D HNNH NOESY
3D HNCO/ HN(CA)CO




NMR restraint
optimization

3D structure
model generation



Medium-range and long-
range NOE distance
restraints




- "Broken" OpenFold
- nElt (248 amino acids)
- Only 4D HCNH NOESY spectrum

1.8 mM, 20 mM sodium phosphate (pH 6.5), 100 mM NaCl, 5% D2O, 37 °C.


Video on [YouTube](#)

4D-GRAPHS: protein structure from 2x 4D spectra

Final model



Explicit solvent equilibration





3D structure ensemble



4D Experiments have Lower Sensitivity: the case of CAII (29 kDa)

- **Overlay of HC-C projection** from 4D NOESY obtained from **273 μM** vs **600 μM** samples.
- 3D structure solved using **1x4D and 4x3D spectra on 950 MHz**: 4D HCNH NOESY, 3D HNCACB / 3D HN(CO)CACB, 3D HNCOC / 3D HN(CA)CO. Total measurement time **21 days**.




Sensitive experimental protocol for backbone assignment

Spectrum	Visible Nuclei	Length
3D-HN(CA)NNH	$N(i)-H(i)-N(i+1)$	3 days
3D-H(NCA)NNH	$N(i)-H(i)-H(i+1)$	3 days
HNCACB	$N(i-1)-H(i-1)-CA(i-1 \text{ or } i)-CB(i-1 \text{ or } i)$	3 days
HN(CO)CACB	$N(i-1)-H(i-1)-CA(i)-CB(i)$	3days
HN(CA)CO	$N(i-1)-H(i-1)-C'(i-1 \text{ or } i)$	1.5 days
HNCO	$N(i-1)-H(i-1)-C'(i)$	1.5 days

disordered regions; both ordered and disordered regions

- Suitable for protein concentrations 200-400 μM
- Bad proton peak dispersion in IDPs leads to crowding in 3D-H(NCA)NNH spectrum (right image).
- If crowding is excessive, then 5D experiments must be employed.



5D experiments for backbone assignment


RNA polymerase δ subunit, 20.3 kDa, 172 residues, 800 μ M

Disordered C-terminal region (81 residues)


GIKQYSQEE LKEMALVEIA HELFEEHKKP VPFQELLNEI
 ASLLGVKKEE LGDRIAQFYT DLNIDGRFLA LSDQTWGLRS
 WYPYDQLDEE TQPTVKAKKK KAKKAVEEDL DLDEFEEIDE
DDLDEVEE ELDLEADDFD EEDLDEDDDD LEIEEDIIDE
DDEDYDEEE EIK

5D HN(CA)CONH



J Biomol NMR. 2010 Nov;48(3):169-77.



- 3D experiments for sequential assignment are inappropriate for this case.




1H,15N-HSQC spectrum




5D experiments for backbone assignment

GIKQYSQEE LKEMALVEIA HELFEEHKKP VPFQELLNEI
 ASLLGVKKEE LGDRIAQFYT DLNIDGRFLA LSDQTWGLRS
 WYPYDQLDEE TQPTVKAKKK KAKKAVEEDL DLDEFEEIDE
DDLDLDEVEE ELDLEADDFD EEDLEDEDDD LEIEEDIIDE
DEDYDDEEE EIK


- Sequential repeats cause severe clustering of backbone N-H peaks, even for 5D HN(CA)CONH.




D159



E160



D161





D162

Top: C α -C' cross-sections from 5D CACONCACO.

Right: plane from 3D HNCO showing the region around **D161** and **E160**.

5D CACONCACO

J Biomol NMR. 2011 May;50(1):1-11.



Additional 5D and 3D experiments

5D CACONCACO has **higher resolution** than **5D HN(CA)CONH** by avoiding the crowded HN dimension, but requires **higher protein concentration (>600 μM)** or **longer measurement**.

After measuring the 5D of the apo form, **3D titration experiments** can be employed to **map backbone interactions** with other molecules:



- **3D HNCO** for **5D HN(CA)CONH**.
- **3D CA(CO)NCA(CO)** for **5D CACONCACO**.

Two additional **5D experiments** provide **chemical shifts of aliphatic side chain** atoms: **HabCabCONH**, **HC(CC-TOCSY)CONH**

Fragment Screening by Target-Observed NMR:

(A) Cartoon depiction of target-observed NMR binding assays. Yellow regions experience chemical shift changes upon fragment binding.

(B) 2D ^1H - ^{15}N or ^1H - ^{13}C HSQC experiments detect **weak** fragment binding to protein target A and map binding sites with known resonance assignments. Boxed cross-peaks indicate perturbed residues.



AI | ffinity contributes to the NMR community







- GitHub tutorials: https://github.com/AI-ffinity/nmr_tutorials
- Topics covered:
 - Setting up 1D to 4D protein experiments in Topspin.
 - Processing non-uniformly sampled (NUS) 3D and 4D spectra.
 - Peak picking and other spectra processing with POKY.
- Future video tutorials on YouTube.

NMR Tutorials




This is the collection of tutorials which aims to help one setting up, running and processing NMR experiments.

Contents

	Setting up 4D NMR experiments for 4D-GRAPHS.
	General tips on navigating NMR Pipe ecosystem.
	Processing NUS data
	How to process spectra in TopSpin.
	How to analyze spectra in SPARKY.
	How to analyze spectra in POKY - the successor of NMRFAM SPARKY.

Privileged access to full-fledged biophysical facilities



- **structure determination** (NMR, X-ray, SAXS)
- **compound screening** (MST, SPR)
- **binding validation & interactions mapping** (HDX-MS, CD, SEC, ITC)

Joint Drug Development







AIffinity
MOLECULAR DESIGN



CEITEC


Central European Institute of Technology
BRNO | CZECH REPUBLIC

NEXMR

Indication	Target	Drug type	Hit discovery	Hit to Lead	Lead Optimization	Pre-clinical Development
Prostate cancer	Androgen Receptor	PROTAC 				
Colorectal cancer	Epigenetic Regulator	Small mol. 				

安宏生醫
AnHorn Medicines
Innovation · New Therapeutics

MUNI Department of Chemistry
SCI



AIffinity
MOLECULAR DESIGN

www.aiffinity.com

info@aiffinity.com

Purkyňova 127, 612 00 Brno-Medlánky, Czech Republic

AI|ffinity Team (total FTE 8.5)



Thomas Evangelidis,
M.Res., M.Phil., Ph.D.
Founder, Chief Executive Officer
& Chief Technology Officer



Lukasz Kozackiewicz,
M.Sc., Ph.D., M.Eng.
Computational Biology Software Developer



Martina Poukarová,
M.BA.
Back-Office Manager



Marcela Mádlíková,
M.Sc.
Protein Biochemist



Vaclav Hanzl,
M.Eng., Ph.D.
Chief Software Engineer




Íñigo Alcalde,
M.Sc., Ph.D.
Computational Biophysics
Software Developer



Jakub Jakubec,
M.Sc.
PhD Student



Tereza Vučková,
M.Sc.
Protein Biochemist



Alzbeta Tuerkova,
M.Sc., Ph.D., M.BA.
Operations & Development Manager



Ekaterina Burakova,
M.Sc., Ph.D.
NMR & Data Scientist



Khanh Nguyễn Tấn,
M.Sc.
PhD Student

Scientific advisors



Pavel Polishchuk

Cheminformatics & Drug Design



Václav Veverka

NMR & Drug Design



Karel Kubíček

Protein NMR



Jiří Filipovič

High-performance computing & automatization



Daniel Svozil

Cheminformatics & Drug Design

Business advisors



Vojtěch Kadlec



Veronika Štěpánková





AIffinity
MOLECULAR DESIGN

"Focus and excel"

AIffinity s.r.o.
IČO 11992719
Purkyňova 127,
612 00 Brno-Medlánky,
Czech Republic

www.aiffinity.com

info@aiffinity.com



Dr. Thomas Evangelidis

Founder & CEO

tevang@aiffinity.com

Supported by:

